ES2295206T3 - Metodo para supervisar el efecto de inhibidores de catepsina s. - Google Patents

Metodo para supervisar el efecto de inhibidores de catepsina s. Download PDF

Info

Publication number
ES2295206T3
ES2295206T3 ES01968093T ES01968093T ES2295206T3 ES 2295206 T3 ES2295206 T3 ES 2295206T3 ES 01968093 T ES01968093 T ES 01968093T ES 01968093 T ES01968093 T ES 01968093T ES 2295206 T3 ES2295206 T3 ES 2295206T3
Authority
ES
Spain
Prior art keywords
cathepsin
inhibitors
effect
class
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01968093T
Other languages
English (en)
Spanish (es)
Inventor
Robin Thurmond
Siquan Sun
Lars Karlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of ES2295206T3 publication Critical patent/ES2295206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
ES01968093T 2000-09-06 2001-08-24 Metodo para supervisar el efecto de inhibidores de catepsina s. Expired - Lifetime ES2295206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23048400P 2000-09-06 2000-09-06
US230484P 2000-09-06

Publications (1)

Publication Number Publication Date
ES2295206T3 true ES2295206T3 (es) 2008-04-16

Family

ID=22865403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01968093T Expired - Lifetime ES2295206T3 (es) 2000-09-06 2001-08-24 Metodo para supervisar el efecto de inhibidores de catepsina s.

Country Status (10)

Country Link
US (1) US7026132B2 (fr)
EP (1) EP1315966B1 (fr)
JP (1) JP2004508553A (fr)
AT (1) ATE374945T1 (fr)
AU (1) AU2001288369A1 (fr)
CA (1) CA2421558A1 (fr)
DE (1) DE60130784T2 (fr)
DK (1) DK1315966T3 (fr)
ES (1) ES2295206T3 (fr)
WO (1) WO2002021129A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784288B2 (en) 2001-11-08 2004-08-31 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of monkey cathepsin S
US6780985B2 (en) 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
WO2006125105A2 (fr) * 2005-05-19 2006-11-23 Wyeth Methodes et compositions de traitement et de diagnostic d'une sclerose en plaques
EP2436776A1 (fr) 2010-10-01 2012-04-04 F. Hoffmann-La Roche AG Procédé pour la surveillance de l'inhibition de la cathepsine S
EP3194610B1 (fr) * 2014-09-18 2019-11-13 F.Hoffmann-La Roche Ag Anticorps anti li p10

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
WO1997010335A1 (fr) * 1995-09-14 1997-03-20 Universität Tübingen Polypeptide recombine contenant la sequence primaire de la chaine invariante avec au moins une sequence primaire d'un epitope de cellule t specifique ou d'un derive proteique et acides nucleiques codant ledit polypeptide recombine
DK0912601T4 (da) 1996-04-22 2009-03-09 Massachusetts Inst Technology Suppression af immunrespons ved inhibering af cathepsin S
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
WO1999058153A1 (fr) * 1998-05-08 1999-11-18 Brigham & Women's Hospital Procedes de diagnostic et de modulation de l'auto-immunite
US6495333B1 (en) * 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay

Also Published As

Publication number Publication date
EP1315966A4 (fr) 2005-07-27
EP1315966B1 (fr) 2007-10-03
DE60130784D1 (de) 2007-11-15
EP1315966A1 (fr) 2003-06-04
WO2002021129A1 (fr) 2002-03-14
JP2004508553A (ja) 2004-03-18
AU2001288369A1 (en) 2002-03-22
US7026132B2 (en) 2006-04-11
CA2421558A1 (fr) 2002-03-14
DK1315966T3 (da) 2008-01-02
ATE374945T1 (de) 2007-10-15
US20020028435A1 (en) 2002-03-07
DE60130784T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
ES2429088T3 (es) Procedimientos de interrupción mejorados para un proceso de inactivación de glóbulos rojos
ES2235806T3 (es) Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr.
ES2318459T3 (es) Metodo y kit para la medicion de la activacion de las celulas neutrofilas.
HUP0303134A2 (hu) HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és eljárás HIV által indukált antitestek detektálására
Nguyen et al. Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii
CY1106876T1 (el) Συσκευασια και μεθοδος ανιχνευσεως της πρωτεϊνης esm-1
ES2295206T3 (es) Metodo para supervisar el efecto de inhibidores de catepsina s.
CN103183726A (zh) 衍生自人bplp蛋白的肽、编码所述肽的多核苷酸和针对所述肽的抗体
ES2285720T3 (es) Metodo de fabricacion de productos terapeuticos pra la encefalopatia espongiforme transmisible, productos sanguineos y tejidos no infecciosos y metodos para su obtencion.
CA2083150A1 (fr) Antigene synthetique de cellule scenescente
Brown et al. Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine
Alsemgeest et al. First evidence for the existence of multiple isoforms of bovine serum amyloid‐A (apoSAA)
CA2192565A1 (fr) Techniques d'identification et de production de peptides antigeniques et leur utilisation en tant que vaccins
Hidayat et al. Nutrition profile and potency of RGD motif in protein hydrolysate of green peas as an antifibrosis in chronic kidney disease
ATE306666T1 (de) Verfahren zur eiweissanalyse
Dean Structure, function and subcellular localization of a human platelet Ca2+-ATPase
CN101466732A (zh) Iv型胶原样免疫反应性多肽
DK0623145T3 (da) Peptider af caseinomacropeptid, antistoffer mod disse peptider og anvendelser deraf
Vílchez et al. Identification of the major proteins present in the seminal plasma of European eel, and how hormonal treatment affects their evolution. Correlation with sperm quality
JP6044950B2 (ja) 汗腺細胞の検出方法
Jahngen et al. Lens proteins are substrates for the reticulocyte ubiquitin conjugation system
Zigmond Polymorphonuclear leucocyte chemotaxis: detection of the gradient and development of cell polarity.
Słowińska et al. Effect of season on proteases and serine protease inhibitors of Siberian sturgeon (Acipenser baerii Brandt, 1869) semen
Dardenne et al. Interactions between zinc and thymulin
Jiang et al. The Presence of a C1‐Inhibitor‐Like Molecule (C1‐INH‐L) On Human Sperm: Its Involvement in Sperm Motility